FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005859098> ?p ?o ?g. }

• W2005859098 endingPage "445" @default.
• W2005859098 startingPage "442" @default.
• W2005859098 abstract "Background Anaphylaxis associated with omalizumab treatment is a growing concern. The broader context in which omalizumab-associated allergic reactions occur has not been well described. Objective To identify and characterize recently reported anaphylactic reactions associated with omalizumab administration. Methods The US Food and Drug Administration Adverse Event Reporting System reports between January 1, 2007, and June 30, 2008, were queried for new reactions primarily suspected to be due to omalizumab. Reaction characteristics were analyzed for a reaction descriptor of anaphylactic or anaphylactoid shock or reaction and for dermal, respiratory, cardiovascular, and gastrointestinal reaction descriptor terms that in combination could be interpreted as constituting anaphylaxis. Associated narratives for these reports were obtained and were examined further. Results There were 85 cases with an anaphylaxis descriptor and 33 cases without a descriptor of anaphylaxis but with multisystem allergic reactions (mostly respiratory and skin or mucosal) that were consistent with anaphylaxis. Of these 118 cases, 32 were after the first dose and 14 were after the second dose of omalizumab. Seventy-seven of the 118 cases were categorized as requiring hospital admission or prolongation, had life-threatening reactions, underwent treatment with epinephrine or corticosteroids, or had omalizumab treatment withheld or discontinued. Nineteen of the 118 reactions were described as occurring within 1 hour of omalizumab injection. Conclusions Allergic reactions to omalizumab continue to be reported. Some patients not labeled as having anaphylaxis have multisystem allergic reactions consistent with anaphylaxis, raising questions about the adequacy of the Food and Drug Administration categorizations. The characteristics of these patient reports point toward a spectrum of systemic allergic reactions associated with omalizumab use. Anaphylaxis associated with omalizumab treatment is a growing concern. The broader context in which omalizumab-associated allergic reactions occur has not been well described. To identify and characterize recently reported anaphylactic reactions associated with omalizumab administration. The US Food and Drug Administration Adverse Event Reporting System reports between January 1, 2007, and June 30, 2008, were queried for new reactions primarily suspected to be due to omalizumab. Reaction characteristics were analyzed for a reaction descriptor of anaphylactic or anaphylactoid shock or reaction and for dermal, respiratory, cardiovascular, and gastrointestinal reaction descriptor terms that in combination could be interpreted as constituting anaphylaxis. Associated narratives for these reports were obtained and were examined further. There were 85 cases with an anaphylaxis descriptor and 33 cases without a descriptor of anaphylaxis but with multisystem allergic reactions (mostly respiratory and skin or mucosal) that were consistent with anaphylaxis. Of these 118 cases, 32 were after the first dose and 14 were after the second dose of omalizumab. Seventy-seven of the 118 cases were categorized as requiring hospital admission or prolongation, had life-threatening reactions, underwent treatment with epinephrine or corticosteroids, or had omalizumab treatment withheld or discontinued. Nineteen of the 118 reactions were described as occurring within 1 hour of omalizumab injection. Allergic reactions to omalizumab continue to be reported. Some patients not labeled as having anaphylaxis have multisystem allergic reactions consistent with anaphylaxis, raising questions about the adequacy of the Food and Drug Administration categorizations. The characteristics of these patient reports point toward a spectrum of systemic allergic reactions associated with omalizumab use." @default.
• W2005859098 created "2016-06-24" @default.
• W2005859098 creator A5043340508 @default.
• W2005859098 creator A5082841163 @default.
• W2005859098 creator A5089972321 @default.
• W2005859098 date "2009-11-01" @default.
• W2005859098 modified "2023-09-28" @default.
• W2005859098 title "Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008" @default.
• W2005859098 cites W1520005604 @default.
• W2005859098 cites W1997241873 @default.
• W2005859098 cites W2004147651 @default.
• W2005859098 cites W2010946738 @default.
• W2005859098 cites W2017244185 @default.
• W2005859098 cites W2019163755 @default.
• W2005859098 cites W2024599039 @default.
• W2005859098 cites W2052951012 @default.
• W2005859098 cites W2063677207 @default.
• W2005859098 cites W2085752173 @default.
• W2005859098 cites W2142877422 @default.
• W2005859098 doi "https://doi.org/10.1016/s1081-1206(10)60366-3" @default.
• W2005859098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19927545" @default.
• W2005859098 hasPublicationYear "2009" @default.
• W2005859098 type Work @default.
• W2005859098 sameAs 2005859098 @default.
• W2005859098 citedByCount "24" @default.
• W2005859098 countsByYear W20058590982012 @default.
• W2005859098 countsByYear W20058590982013 @default.
• W2005859098 countsByYear W20058590982014 @default.
• W2005859098 countsByYear W20058590982015 @default.
• W2005859098 countsByYear W20058590982016 @default.
• W2005859098 countsByYear W20058590982017 @default.
• W2005859098 countsByYear W20058590982018 @default.
• W2005859098 countsByYear W20058590982019 @default.
• W2005859098 countsByYear W20058590982020 @default.
• W2005859098 countsByYear W20058590982021 @default.
• W2005859098 countsByYear W20058590982023 @default.
• W2005859098 crossrefType "journal-article" @default.
• W2005859098 hasAuthorship W2005859098A5043340508 @default.
• W2005859098 hasAuthorship W2005859098A5082841163 @default.
• W2005859098 hasAuthorship W2005859098A5089972321 @default.
• W2005859098 hasConcept C141105273 @default.
• W2005859098 hasConcept C151730666 @default.
• W2005859098 hasConcept C159654299 @default.
• W2005859098 hasConcept C16005928 @default.
• W2005859098 hasConcept C203014093 @default.
• W2005859098 hasConcept C207480886 @default.
• W2005859098 hasConcept C2775859304 @default.
• W2005859098 hasConcept C2775933838 @default.
• W2005859098 hasConcept C2778564945 @default.
• W2005859098 hasConcept C2779060952 @default.
• W2005859098 hasConcept C2779343474 @default.
• W2005859098 hasConcept C2909843257 @default.
• W2005859098 hasConcept C2994354051 @default.
• W2005859098 hasConcept C42219234 @default.
• W2005859098 hasConcept C71924100 @default.
• W2005859098 hasConcept C86803240 @default.
• W2005859098 hasConceptScore W2005859098C141105273 @default.
• W2005859098 hasConceptScore W2005859098C151730666 @default.
• W2005859098 hasConceptScore W2005859098C159654299 @default.
• W2005859098 hasConceptScore W2005859098C16005928 @default.
• W2005859098 hasConceptScore W2005859098C203014093 @default.
• W2005859098 hasConceptScore W2005859098C207480886 @default.
• W2005859098 hasConceptScore W2005859098C2775859304 @default.
• W2005859098 hasConceptScore W2005859098C2775933838 @default.
• W2005859098 hasConceptScore W2005859098C2778564945 @default.
• W2005859098 hasConceptScore W2005859098C2779060952 @default.
• W2005859098 hasConceptScore W2005859098C2779343474 @default.
• W2005859098 hasConceptScore W2005859098C2909843257 @default.
• W2005859098 hasConceptScore W2005859098C2994354051 @default.
• W2005859098 hasConceptScore W2005859098C42219234 @default.
• W2005859098 hasConceptScore W2005859098C71924100 @default.
• W2005859098 hasConceptScore W2005859098C86803240 @default.
• W2005859098 hasIssue "5" @default.
• W2005859098 hasLocation W20058590981 @default.
• W2005859098 hasLocation W20058590982 @default.
• W2005859098 hasOpenAccess W2005859098 @default.
• W2005859098 hasPrimaryLocation W20058590981 @default.
• W2005859098 hasRelatedWork W181418607 @default.
• W2005859098 hasRelatedWork W2005859098 @default.
• W2005859098 hasRelatedWork W2020556773 @default.
• W2005859098 hasRelatedWork W2103640113 @default.
• W2005859098 hasRelatedWork W2417354250 @default.
• W2005859098 hasRelatedWork W2433416762 @default.
• W2005859098 hasRelatedWork W2810441482 @default.
• W2005859098 hasRelatedWork W2946453069 @default.
• W2005859098 hasRelatedWork W3005698903 @default.
• W2005859098 hasRelatedWork W3035986814 @default.
• W2005859098 hasVolume "103" @default.
• W2005859098 isParatext "false" @default.
• W2005859098 isRetracted "false" @default.
• W2005859098 magId "2005859098" @default.
• W2005859098 workType "article" @default.